Research & Development: Page 2

  • brain pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    After Amylyx drug failure, what’s next for ALS?

    The company’s combo treatment Relyvrio was approved in 2022, but after failing a phase 3 trial, may be pulled from the market.

    By • March 15, 2024
  • U.S. President Joe Biden
    Image attribution tooltip
    Alex Wong/Getty Images via Getty Images
    Image attribution tooltip
    Q&A

    Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake

    A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.

    By • March 14, 2024
  • test tube gene Explore the Trendline➔
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Cell and gene therapies

    How the industry is overcoming hurdles in cell and gene therapy space and pushing for the next generation of treatments.

    By PharmaVoice staff
  • liquid biopsy
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    As colorectal deaths rise among younger people, a screening tool could help pinpoint more patients

    As colorectal deaths rise among younger people, a diagnostic could help pinpoint more patients.

    By Alexandra Pecci • March 12, 2024
  • Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The silver lining around Lilly’s Alzheimer’s delay could be a future with better drugs

    Although a regulatory delay for Eli Lilly’s donanemab in Alzheimer’s disease is a competitive setback, researchers have their eye on better drug development as a result.

    By • March 12, 2024
  • lightbulb brain
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Neurvati touts fresh, ‘synergistic’ investment model in neuroscience R&D

    The Blackstone Life Sciences-backed company plans to focus on later-stage assets to help derisk development.

    By Kelly Bilodeau • March 11, 2024
  • Bobak Azamian horizontal no logo
    Image attribution tooltip
    Permission granted by Tarsus Pharmaceuticals
    Image attribution tooltip
    Q&A

    Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category

    The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.

    By • March 8, 2024
  • Signs for Johnson & Johnson are seen on company offices in California.
    Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J’s growing rare disease focus brings a potential multi-use treatment to the table

    The head of J&J’s autoantibody programs believes nipocalimab is unique among potential rare disease drugs because it can harness a common thread among them.

    By • March 7, 2024
  • schizophrenia
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Big hopes for schizophrenia treatment rely on a deep pipeline of new approaches

    Innovation in schizophrenia has been slow, and patients are often left with few options — but pharmas contribute to a robust lineup of candidates that could improve care.

    By Kelly Bilodeau • March 6, 2024
  • Dr. Marc Conant, chief medical officer, American Gene Technologies
    Image attribution tooltip
    Permission granted by Natalie Ferguson/American Gene Technologies
    Image attribution tooltip
    Profile

    HIV isn’t ‘solved,’ but a doctor who treated some of the first patients hopes to finally deliver a cure

    From San Francisco in the 80s to a gene therapy prospect, Dr. Marcus Conant looks back on his long fight against the virus — and if the industry is close to ending the epidemic.

    By • March 5, 2024
  • The staff of CG Oncology rings the opening bell at Nasdaq as confetti falls.
    Image attribution tooltip
    Permission granted by Nasdaq, Inc.
    Image attribution tooltip

    Biotech IPOs heated up to start 2024. Will the surge last?

    Following the sector’s best IPO start in three years, industry insiders shared what they expect to see in the months ahead. 

    By Gwendolyn Wu , Ben Fidler • March 5, 2024
  • lots of colorful pills
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Black Diamond looks to outwit cancer mutations

    Why the company’s novel therapeutics could have a competitive edge in a crowded cancer indication.

    By Kelly Bilodeau • March 4, 2024
  • Neuron ALS
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip
    Q&A

    Biogen partner NeuroSense seeks a role in the ALS revolution

    Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.

    By • Feb. 29, 2024
  • A man in a blue shirt looks into the camera for a headshot photograph.
    Image attribution tooltip
    Permission granted by Lindus Health
    Image attribution tooltip

    Can a top scientist and Moderna co-founder change the CRO game?

    From his advisory board role at Lindus Health, Robert Langer is aiming to overcome challenges in the CRO market.

    By • Feb. 28, 2024
  • Gianluca Pirozzi header
    Image attribution tooltip
    Permission granted by Gianluca Pirozzi
    Image attribution tooltip
    Profile

    Behind a big-name rare disease biotech, an exec draws from personal experience

    The personal impact of rare disease has shaped Gianluca Pirozzi, a senior vice president at AstraZeneca’s Alexion, as a parent and drug developer.

    By Alexandra Pecci • Feb. 27, 2024
  • blue dosing pen for semaglutide
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Ozempic for liver disease? Weight loss drugs could have even more to offer

    GLP-1 drugs indications could expand as research shows potential benefits in treating MASH, where pharma has failed in the past.

    By Kelly Bilodeau • Feb. 26, 2024
  • Moderna company name on side of building
    Image attribution tooltip
    Maddie Meyer via Getty Images
    Image attribution tooltip
    Q&A

    For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test

    Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.

    By • Feb. 23, 2024
  • Iovance hallway
    Image attribution tooltip
    Permission granted by Iovance Biotherapeutics
    Image attribution tooltip

    Behind the breakthrough cancer therapy that just won a historic FDA nod

    The first-of-its-kind TIL therapy for solid tumors developed by Iovance Biotherapeutics won FDA approval last week.

    By Kelly Bilodeau • Feb. 21, 2024
  • chemist in lab with dropper
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    4 biotechs to watch in 2024

    A splashy IPO, first-in-class treatments and upcoming approval dates are a few reasons we’ve got our eyes on these biotechs this year.

    By Alexandra Pecci • Feb. 21, 2024
  • One of Kite Pharma's buildings.
    Image attribution tooltip
    Courtesy of Kite Pharma, Inc.
    Image attribution tooltip

    Kite’s next-gen CAR-T aims include quicker production and more disease targets

    While buzz builds around “off the shelf” CAR-T cell therapies, Kite is staying competitive with a shorter manufacturing turnaround and a focus on broadening applications.

    By Kelly Bilodeau • Feb. 20, 2024
  • IoT and AI design
    Image attribution tooltip
    Permission granted by Avenga
    Image attribution tooltip
    Sponsored by Avenga

    Value and potential of IoT and AI for chronic diseases treatment

    A significant growth is predicted for both AI and IoT in healthcare. By 2030, the AI market is expected to reach $187.95 billion USD, while the IoT market is projected to climb even higher to $312.7 billion USD.

    By Olena Domanska, Data Science Engineering Manager at Avenga • Feb. 20, 2024
  • paper pie chart hand placing a piece
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Pharma CFOs need R&D vigilance in tough economic times

    Belt tightening and streamlined portfolios are critical in 2024 amid continued economic uncertainty.

    By • Feb. 16, 2024
  • pill loading
    Image attribution tooltip
    stock via Getty Images
    Image attribution tooltip

    ‘Hey, AI: Is Zoloft effective for me?’ Tech’s foray into predictive prescribing

    Researchers are unleashing the powers of AI for precision medicine, drug development and more.

    By Alexandra Pecci • Feb. 15, 2024
  • A man in a suit looking at the camera
    Image attribution tooltip
    Courtesy of Biogen
    Image attribution tooltip

    The roadblocks faced by Biogen are many, but execs point to an R&D-focused turnaround

    A disappointing few years for Biogen have led leadership to use new drug launches as fuel for an about-face.

    By • Feb. 15, 2024
  • Brain MRI
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    A new (old) mind-opening tool in the fight against Alzheimer’s disease

    A new use for an existing ultrasound technology is seeing early success in getting medications past the blood-brain barrier.

    By Kelly Bilodeau • Feb. 12, 2024
  • Dr. Robert Califf, FDA commissioner, speaking at a podium with hands up
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    FDA inches closer to defining its regulatory role in AI

    Commissioner Dr. Robert Califf signals how the FDA will consider AI in drug development and how the agency may use the emerging technology in the future.

    By • Feb. 12, 2024